Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | N581I |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | BRAF N581I lies within the protein kinase domain of the Braf protein (UniProt.org). N581I results in low Braf kinase activity and Ras-dependent activation of Erk signaling in cell culture (PMID: 28783719), however, also results in increased transformation ability compared to wild-type Braf in culture (PMID: 29533785), and therefore, its effect on Braf protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF N581X BRAF N581I |
Transcript | NM_004333.6 |
gDNA | chr7:g.140753393T>A |
cDNA | c.1742A>T |
Protein | p.N581I |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004333.6 | chr7:g.140753393T>A | c.1742A>T | p.N581I | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140753393T>A | c.1742A>T | p.N581I | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140753393T>A | c.1742A>T | p.N581I | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140753393T>A | c.1742A>T | p.N581I | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140753393T>A | c.1742A>T | p.N581I | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140753393T>A | c.1742A>T | p.N581I | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140753393T>A | c.1742A>T | p.N581I | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140753393T>A | c.1742A>T | p.N581I | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF N581I | colorectal cancer | not predictive | Cetuximab + Irinotecan | Case Reports/Case Series | Actionable | In a clinical study, the combination of Erbitux (cetuximab) with Camptosar (irinotecan) as a first-line therapy resulted in stable disease with progression-free survival of 10.3 months in a patient with metastatic colorectal cancer harboring BRAF N581I (PMID: 31515458). | 31515458 |
BRAF N581I | neuroendocrine carcinoma | predicted - sensitive | Cobimetinib + Vemurafenib | Case Reports/Case Series | Actionable | In a Phase II trial (TAPUR), Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy resulted in a partial response in a patient with neuroendocrine carcinoma harboring BRAF N581I (PMID: 38096472; NCT02693535). | 38096472 |